logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Cancer and Palliative Care

Results

Drugs

July 2021

Afamitresgene autoleucel for advanced synovial sarcoma or myxoid/round cell liposarcoma

Afamitresgene autoleucel is in clinical development for the treatment of advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) in patients who have previously had chemotherapy. Both synovial sarcoma and MRCLS are two different types of soft tissue sarcomas (STS), a rare form of cancer that develops in the tissues that connect, support and surround other …

Drugs

July 2021

Pembrolizumab in combination with lenvatinib, platinum chemotherapy, and pemetrexed for non-small cell lung cancer

The combination of pembrolizumab, lenvatinib, platinum chemotherapy, and pemetrexed is in clinical development for the treatment of metastatic non-squamous non-small cell lung cancer (NSCLC). NSCLC makes up the majority of lung cancers in the UK and at the metastatic stage (stage IV), the disease has already spread from the lungs to other sites. Most patients …

Drugs

July 2021

Nivolumab in combination with ipilimumab for gastric or gastroesophageal junction cancer – first line

Nivolumab in combination with ipilimumab is under development for the treatment of advanced gastric or gastroesophageal junction cancer. Gastric cancer is a malignant tumour originating in the cells of the stomach. Advanced gastric cancer begins in the stomach and spread into the tissues around the stomach, either as locally advanced disease, or it can metastasise …

Drugs

June 2021

Duvelisib for Relapsed or Refractory Chronic Lymphocytic Leukaemia

Duvelisib is an anti-cancer drug in clinical development for adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) after at least two prior therapies. CLL is a type of cancer in which too many white blood cells are produced. As these cells develop abnormally, they are unable to function and fight infection and reduce …

Drugs

June 2021

Glofitamab for relapsed or refractory diffuse large B-cell lymphoma

Glofitamab is in clinical development for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), high grade B cell lymphoma (HGBCL) and primary mediastinal large B-cell lymphoma (PMBCL). HGBCL and PMBCL are subtypes of DLBCL which is a type of blood cancer that develops when white blood cells, called lymphocytes, grow out of …

Drugs

June 2021

Magrolimab in addition to azacitidine for myelodysplastic syndromes – First-line

Magrolimab in addition to azacitidine is in clinical development for the treatment of myelodysplastic syndromes (MDS) in adults. MDS are a group of disorders in which the red blood cells, white blood cells and platelets produced by the bone marrow do not mature normally. Patients with myelodysplastic syndromes can develop tiredness or weakness due to …

Drugs

June 2021

Bintrafusp alfa for advanced, unresectable cervical cancer

Bintrafusp alfa is in clinical development for the treatment of advanced, unresectable, or metastatic cervical cancer. Cervical cancer can be defined as advanced or metastatic when originates in the cervix and spreads to various other parts of the body. If cervical cancer is recurrent, metastatic or persistent, there are limited treatment options, with treatments usually …

June 2021

Pirtobrutinib for mantle cell lymphoma

Pirtobrutinib is currently in clinical development for mantle cell lymphoma (MCL). MCL is a rare type of non-Hodgkin lymphoma (NHL) that usually behaves like a fast-growing lymphoma. It develops when B-cells, white blood cells, become abnormal. The abnormal B-cells usually build up in lymph nodes, but they can affect other parts of the body. MCL …

Drugs

June 2021

Canakinumab in addition to pembrolizumab and platinum-based chemotherapy for locally advanced or metastatic non-small-cell lung cancer (NSCLC)

Canakinumab in addition to pembrolizumab and platinum-based chemotherapy is in clinical development for non-small-cell lung cancer (NSCLC). In the UK, 85% of lung cancers are NSCLC. Advanced cancers can be locally advanced or metastatic. Locally advanced (stage III) is cancer that has grown outside the body part it started in but has not yet spread …

Drugs

June 2021

Tisagenlecleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma – second line

Tisagenlecleucel is in clinical development for second-line treatment of relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). NHL is a type of blood cancer that develops when white blood cells, called lymphocytes, grow out of control. The lymphocytes lose their infection fighting ability, making the body more susceptible to infection. Relapsed cancer refers to cancer …

Get Alerts